- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| AROA BIOSURGERY Aktie jetzt für 0€ handeln | |||||
| 06:14 | AROA BIOSURGERY LIMITED: Initial Director's Interest Notice - PS | - | ASX | ||
| 06:12 | AROA BIOSURGERY LIMITED: Final Director's Interest Notice - JP | - | ASX | ||
| Fr | AROA BIOSURGERY LIMITED: Paul Shearer to join Aroa Board and John Pinion to Retire | 1 | ASX | ||
| 15.10. | AROA BIOSURGERY LIMITED: Investor Presentation | - | ASX | ||
| 15.10. | AROA BIOSURGERY LIMITED: September 2025 Quarterly Report and Appendix 4C | - | ASX | ||
| 10.10. | AROA BIOSURGERY LIMITED: Change in substantial holding | 1 | ASX | ||
| 09.10. | AROA BIOSURGERY LIMITED: Notification of Quarterly Results Webinar | 1 | ASX | ||
| 08.10. | AROA BIOSURGERY LIMITED: Notification of cessation of securities - ARX | 1 | ASX | ||
| 23.09. | AROA BIOSURGERY LIMITED: Change of Director's Interest Notice - BW | - | ASX | ||
| 23.09. | AROA BIOSURGERY LIMITED: Notification regarding unquoted securities - ARX | - | ASX | ||
| 10.09. | Aroa to hit right note as US skin substitute rules set for change | 1 | Stockhead | ||
| 20.08. | AROA BIOSURGERY LIMITED: Results of Annual General Meeting | - | ASX | ||
| 20.08. | AROA BIOSURGERY LIMITED: CEO Presentation - AGM | - | ASX | ||
| 20.08. | AROA BIOSURGERY LIMITED: Chairman's Address - AGM | - | ASX | ||
| 06.08. | AROA BIOSURGERY LIMITED: Notice of Annual General Meeting/Proxy Form | - | ASX | ||
| 29.07. | AROA BIOSURGERY LIMITED: Investor Presentation | - | ASX | ||
| 29.07. | AROA BIOSURGERY LIMITED: June 2025 Quarterly Report and Appendix 4C | - | ASX | ||
| 25.07. | AROA BIOSURGERY LIMITED: Change of Director's Interest Notice - PM | - | ASX | ||
| 25.07. | AROA BIOSURGERY LIMITED: Change of Director's Interest Notice - JP | - | ASX | ||
| 25.07. | AROA BIOSURGERY LIMITED: Change of Director's Interest Notice - JM | - | ASX |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,25 | +0,06 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| EVOTEC | 7,006 | -0,68 % | EQS-News: Evotec SE: Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
27.10.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| CUREVAC | 4,592 | -0,65 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| MODERNA | 21,925 | -7,18 % | Moderna: Neues zur Tumor-Therapie mRNA-2808 | Moderna hat den ersten Patient in einer klinischen Phase-1/2-Studie mit dem Wirkstoffkandidaten mRNA-2808 behandelt. Der mRNA-basierte T-Cell-Engager wird nach Angaben des US-Biotechunternehmens vom... ► Artikel lesen | |
| NOVAVAX | 7,010 | -3,89 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| HEIDELBERG PHARMA | 3,010 | +0,67 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma präsentiert neue klinische Daten zum führenden ADC-Kandidaten HDP-101 auf dem World ADC Congress 2025 und führt Webinar durch | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Studienergebnisse
Heidelberg Pharma präsentiert neue klinische Daten zum führenden ADC-Kandidaten HDP-101 auf dem World ADC Congress... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,120 | +3,92 % | INOVIO Pharmaceuticals, Inc.: INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults | Recurrent respiratory papillomatosis (RRP) is a rare HPV-related disease of the respiratory tract with significant unmet need
INO-3107 previously received... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| DYNAVAX | 8,984 | +0,97 % | Dynavax Technologies: Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial | Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profile
Newly presented data outline robust... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 45,620 | -1,74 % | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen | |
| VAXART | 0,327 | +20,07 % | Vaxart, Inc.: Vaxart Announces Withdrawal of Reverse Stock Split Proposal | SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
| IBIO | 1,420 | +2,90 % | iBio, Inc. - 8-K, Current Report | ||
| ARBUTUS BIOPHARMA | 4,102 | -0,77 % | Arbutus Biopharma Corporation: Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,300 | -2,65 % | FDA-Sonderstatus für Krebstherapie beflügelt Cellectar-Aktie |
AROA BIOSURGERY LIMITED gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AROA BIOSURGERY LIMITED finden Sie auf Wallstreet Online.